Follow Healthline   |   Healthline on TwitterTwitter   |   Healthline on FacebookFacebook
Symptom Search   |   Treatment Search   |   Doctor Search   |   Drug Search

Drug Notebook

Drug Info Tools
Search by color, shape and markings. click here
Check any 2 drugs for interactions. click here
Compare any two drugs side by side. click here
Medicare's drug plans are subsidized by the US federal government and offered through insurers.
Advertisement
Marketplace
Licensed from
levodopa
Page: < Back 1 2 3 4

Advice to Patients

  • Importance of taking levodopa/carbidopa at regular intervals as scheduled by the clinician. Importance of not altering the prescribed dosage regimen or adding other antiparkinsonian drugs.
  • Advise patient not to chew or crush extended-release tablets; however, tablets may be halved.
  • For patients taking orally disintegrating tablets, advise to gently remove the tablet from the bottle with dry hands just before administering a dose and then placing the tablet on the tongue to dissolve and be swallowed with saliva.
  • Importance of informing patients with phenylketonuria that the orally disintegrating tablets contain aspartame.
  • Advise patient to notify clinician if abnormal involuntary movements appear or get worse; dosage adjustment may be needed.
  • Advise patient of expected onset and duration of effect.
  • Possibility that dark color (red, brown, black) may appear in saliva, urine, or sweat; garments may be discolored.
  • Advise patient that a change in diet to food high in protein may delay absorption of levodopa and reduce systemic availability. Excess acidity may delay absorption.
  • Importance of informing clinician of existing or contemplated concomitant therapy, including prescription and OTC drugs and dietary or herbal products.
  • Importance of women informing clinician if they are or plan to become pregnant or plan to breast-feed.
  • Importance of advising patients of other important precautionary information. (See Cautions.)

Preparations

Excipients in commercially available drug preparations may have clinically important effects in some individuals; consult specific product labeling for details.

Carbidopa
RoutesDosage FormsStrengthsBrand NamesManufacturer
OralTablets25 mg (of anhydrous carbidopa)

Lodosyn® (scored)

Bristol-Myers Squibb
Carbidopa-Levodopa (Co-careldopa)
RoutesDosage FormsStrengthsBrand NamesManufacturer
OralTabletsCarbidopa 10 mg (of anhydrous carbidopa) and Levodopa 100 mg*Carbidopa and Levodopa TabletsPurepac, Teva, UDL

Sinemet® (scored)

Bristol-Myers Squibb
Carbidopa 25 mg (of anhydours carbidopa) and Levodopa 100 mg*Carbidopa and Levodopa TabletsElan, Endo, IVAC, Purepac, Teva, UDL

Sinemet® (scored)

Bristol-Myers Squibb
Carbidopa 25 mg (of anhydrous carbidopa) and Levodopa 250 mg*Carbidopa and Levodopa TabletsEndo, Purepac, Teva, UDL

Sinemet® (scored)

Bristol-Myers Squibb
Tablets, extended-releaseCarbidopa 50 mg (of anhydrous carbidopa) and Levodopa 200 mg*Carbidopa and Levodopa Extended-release TabletsApotex, Ethex, Global, Mylan, UDL

Sinemet® CR (scored)

Bristol-Myers Squibb
Carbidopa 25 mg (of anhydrous carbidopa) and Levodopa 100 mg*Carbidopa and Levodopa Extended-release Tablets (scored)Apotex, Global, Mylan, UDL

Sinemet® CR

Bristol-Myers Squibb
Tablets, orally disintegratingCarbidopa 10 mg (of anhydrous carbidopa) and Levodopa 100 mg

Parcopa® (with aspartame; scored)

Schwarz
Carbidopa 25 mg (of anhydrous carbidopa) and Levodopa 100 mg

Parcopa® (with aspartame; scored)

Schwarz
Carbidopa 25 mg (of anhydrous carbidopa) and Levodopa 250 mg

Parcopa® (with aspartame; scored)

Schwarz
* available from one or more manufacturer, distributor, and/or repackager by generic (nonproprietary) name
Other Carbidopa Combinations
RoutesDosage FormsStrengthsBrand NamesManufacturer
Oral
Tablets, film-coatedCarbidopa 12.5 mg (of anhydrous carbidopa) with Entacapone 200 mg and Levodopa 50 mg

Stalevo® (with povidone)

Novartis
Carbidopa 25 mg (of anhydrous carbidopa) with Entacapone 200 mg and Levodopa 100 mg

Stalevo® (with povidone)

Novartis
Carbidopa 37.5 mg (of anhydrous carbidopa) with Entacapone 200 mg and Levodopa 150 mg

Stalevo® (with povidone)

Novartis

Comparative Pricing

This pricing information is subject to change at the sole discretion of DS Pharmacy. This pricing information was updated 09/2009. For the most current and up-to-date pricing information, please visit www.drugstore.com. Actual costs to patients will vary depending on the use of specific retail or mail-order locations and health insurance copays.

Carbidopa-Levodopa 10-100MG Tablets TEVA PHARMACEUTICALS USA90/$34.99 or 180/$65.97
Carbidopa-Levodopa 25-100MG Tablets TEVA PHARMACEUTICALS USA90/$39.99 or 270/$101.98
Carbidopa-Levodopa 25-250MG Tablets TEVA PHARMACEUTICALS USA60/$33.99 or 180/$82.98
Carbidopa-Levodopa CR 25-100MG Controlled-release Tablets MYLAN60/$40.99 or 180/$116.98
Carbidopa-Levodopa CR 50-200MG Controlled-release Tablets MYLAN60/$80.99 or 180/$221.98
Parcopa 10-100MG Dispersible Tablets AZUR PHARMA30/$48.27 or 90/$139.24
Parcopa 25-100MG Dispersible Tablets AZUR PHARMA30/$81.37 or 90/$195.28
Parcopa 25-250MG Dispersible Tablets AZUR PHARMA30/$97.64 or 90/$250.61
Sinemet 10-100MG Tablets B-M SQUIBB U.S. (PRIMARY CARE)90/$91.16 or 270/$256.55
Sinemet 25-100MG Tablets B-M SQUIBB U.S. (PRIMARY CARE)90/$113.4 or 270/$305.96
Sinemet 25-250MG Tablets B-M SQUIBB U.S. (PRIMARY CARE)60/$88.57 or 180/$252.67
Sinemet CR 25-100MG Controlled-release Tablets B-M SQUIBB U.S. (PRIMARY CARE)60/$85.43 or 180/$227.47
Sinemet CR 50-200MG Controlled-release Tablets B-M SQUIBB U.S. (PRIMARY CARE)60/$145.49 or 180/$417.24
Stalevo 100 25-100-200MG Tablets NOVARTIS90/$267.1 or 270/$753.27
Stalevo 150 37.5-150-200MG Tablets NOVARTIS30/$96.43 or 90/$283.27
Stalevo 200 50-200-200MG Tablets NOVARTIS100/$307.12 or 300/$877.44
Stalevo 50 12.5-50-200MG Tablets NOVARTIS30/$93.02 or 90/$267.08

AHFS Drug Information. © Copyright, 1959-2009, Selected Revisions May 2008. American Society of Health-System Pharmacists, Inc., 7272 Wisconsin Avenue, Bethesda, Maryland 20814.

† Use is not currently included in the labeling approved by the US Food and Drug Administration.

Remember, keep this and all other medicines out of the reach of children, never share your medicines with others, and use this medication only for the indication prescribed.


Last Updated: May 01, 2008
Page: < Back 1 2 3 4
Advertisement
Back to Top